{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T15:08:43Z","timestamp":1793200123530,"version":"4.5.0"},"reference-count":24,"publisher":"Japan Surgical Society","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Surg Case Rep"],"published-print":{"date-parts":[[2025]]},"DOI":"10.70352\/scrj.cr.25-0023","type":"journal-article","created":{"date-parts":[[2025,3,18]],"date-time":"2025-03-18T18:12:51Z","timestamp":1742321571000},"page":"n\/a","source":"Crossref","is-referenced-by-count":4,"title":["Hilar Cholangiocarcinoma with Para-Aortic Lymph Node Metastasis Treated with Chemoimmunotherapy and Conversion Surgery: A Case Report"],"prefix":"10.70352","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-7893-5364","authenticated-orcid":false,"given":"Yuma","family":"Yasui","sequence":"first","affiliation":[{"name":"Department of Surgery, Matsuyama Red Cross Hospital, Matsuyama, Ehime, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4116-4135","authenticated-orcid":false,"given":"Koichi","family":"Kimura","sequence":"additional","affiliation":[{"name":"Department of Surgery, Matsuyama Red Cross Hospital, Matsuyama, Ehime, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8589-0038","authenticated-orcid":false,"given":"Norifumi","family":"Iseda","sequence":"additional","affiliation":[{"name":"Department of Surgery, Matsuyama Red Cross Hospital, Matsuyama, Ehime, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshinari","family":"Nobuto","sequence":"additional","affiliation":[{"name":"Department of Surgery, Matsuyama Red Cross Hospital, Matsuyama, Ehime, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroko","family":"Yano","sequence":"additional","affiliation":[{"name":"Department of Surgery, Matsuyama Red Cross Hospital, Matsuyama, Ehime, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuichiro","family":"Kajiwara","sequence":"additional","affiliation":[{"name":"Department of Surgery, Matsuyama Red Cross Hospital, Matsuyama, Ehime, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuro","family":"Watanabe","sequence":"additional","affiliation":[{"name":"Center for Liver-Biliary-Pancreatic Disease, Matsuyama Red Cross Hospital, Matsuyama, Ehime, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"Cao","sequence":"additional","affiliation":[{"name":"Center for Liver-Biliary-Pancreatic Disease, Matsuyama Red Cross Hospital, Matsuyama, Ehime, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michiko","family":"Amano","sequence":"additional","affiliation":[{"name":"Center for Liver-Biliary-Pancreatic Disease, Matsuyama Red Cross Hospital, Matsuyama, Ehime, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takaaki","family":"Tanaka","sequence":"additional","affiliation":[{"name":"Center for Liver-Biliary-Pancreatic Disease, Matsuyama Red Cross Hospital, Matsuyama, Ehime, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hironori","family":"Ochi","sequence":"additional","affiliation":[{"name":"Center for Liver-Biliary-Pancreatic Disease, Matsuyama Red Cross Hospital, Matsuyama, Ehime, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuaki","family":"Azemoto","sequence":"additional","affiliation":[{"name":"Center for Liver-Biliary-Pancreatic Disease, Matsuyama Red Cross Hospital, Matsuyama, Ehime, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhito","family":"Minami","sequence":"additional","affiliation":[{"name":"Department of Surgery, Matsuyama Red Cross Hospital, Matsuyama, Ehime, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryosuke","family":"Minagawa","sequence":"additional","affiliation":[{"name":"Department of Surgery, Matsuyama Red Cross Hospital, Matsuyama, Ehime, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoyuki","family":"Yokota","sequence":"additional","affiliation":[{"name":"Center for Liver-Biliary-Pancreatic Disease, Matsuyama Red Cross Hospital, Matsuyama, Ehime, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Nishizaki","sequence":"additional","affiliation":[{"name":"Department of Surgery, Matsuyama Red Cross Hospital, Matsuyama, Ehime, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"51119","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1) Valle JW, Kelley RK, Nervi B, et al. Biliary tract cancer. Lancet 2021; 397: 428\u201344.","DOI":"10.1016\/S0140-6736(21)00153-7"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2) Khan SA, Davidson BR, Goldin RD, et al. Guidelines for the diagnosis and treatment of cholangiocarcinoma: an update. Gut 2012; 61: 1657\u201369.","DOI":"10.1136\/gutjnl-2011-301748"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3) Okusaka T, Ishii H, Funakoshi A, et al. Phase II study of single-agent gemcitabine in patients with advanced biliary tract cancer. Cancer Chemother Pharmacol 2006; 57: 647\u201353.","DOI":"10.1007\/s00280-005-0095-3"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4) Valle J, Wasan H, Palmer DH, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med 2010; 362: 1273\u201381.","DOI":"10.1056\/NEJMoa0908721"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5) Oh D-Y, Ruth He A, Qin S, et al. Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer. NEJM Evid 2022; 1: EVIDoa2200015.","DOI":"10.1056\/EVIDoa2200015"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6) Kelley RK, Ueno M, Yoo C, et al. Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2023; 401: 1853\u201365.","DOI":"10.1016\/S0140-6736(23)00727-4"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7) Bismuth H, Adam R, L\u00e9vi F, et al. Resection of nonresectable liver metastases from colorectal cancer after neoadjuvant chemotherapy. Ann Surg 1996; 224: 509\u201320; discussion 520\u20132.","DOI":"10.1097\/00000658-199610000-00009"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8) Shoji Y, Kanamori K, Koyanagi K, et al. Conversion surgery for esophageal and esophagogastric junction cancer. Int J Clin Oncol 2024; 29: 1777\u201384.","DOI":"10.1007\/s10147-024-02639-4"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9) Deng H, Liu J, Cai X, et al. Radical minimally invasive surgery after immuno-chemotherapy in Initially-unresectable Stage IIIB non-small cell Lung Cancer. Ann Surg 2022; 275: e600\u20132.","DOI":"10.1097\/SLA.0000000000005233"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10) Iseda N, Itoh S, Toshima T, et al. Outcome of hepatectomy after systemic therapy for hepatocellular carcinoma: a Japanese multicenter study. Surg Today 2024. [Online ahead of print]","DOI":"10.1007\/s00595-024-02930-x"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11) Kato A, Shimizu H, Ohtsuka M, et al. Downsizing chemotherapy for initially unresectable locally advanced biliary tract cancer patients treated with gemcitabine plus cisplatin combination therapy followed by radical surgery. Ann Surg Oncol 2015; 22 (Suppl 3): S1093\u20139.","DOI":"10.1245\/s10434-015-4768-9"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12) Wang S, Wang Y, Zhu C, et al. Conversion surgery intervention versus continued systemic therapy in patients with a response after PD-1\/PD-L1 inhibitor-based combination therapy for initially unresectable biliary tract cancer: a retrospective cohort study. Int J Surg 2024; 110: 4608\u201316.","DOI":"10.1097\/JS9.0000000000001540"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13) Bismuth H, Castaing D, Traynor O. Resection or palliation: priority of surgery in the treatment of hilar cancer. World J Surg 1988; 12: 39\u201347.","DOI":"10.1007\/BF01658484"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14) Kimura K, Minagawa R, Yamaoka T, et al. Transileocolic portal vein embolization increases remnant liver volume after major hepatectomy. In Vivo 2024; 38: 2761\u20136.","DOI":"10.21873\/invivo.13755"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15) Leong EKF, Tan NCH, Pang NQ, et al. Case report: from palliative to potentially curative \u2013 the advent of immunotherapy providing hope to advanced gallbladder adenocarcinoma. Front Immunol 2024; 15: 1353430.","DOI":"10.3389\/fimmu.2024.1353430"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16) Orlandi E, Toscani I, Trubini S, et al. Evolving approaches in advanced gallbladder cancer with complete pathological response using chemo-immunotherapy: a case report. Oncol Lett 2024; 28: 473.","DOI":"10.3892\/ol.2024.14606"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17) Ioka T, Kanai M, Kobayashi S, et al. Randomized phase III study of gemcitabine, cisplatin plus S-1 versus gemcitabine, cisplatin for advanced biliary tract cancer (KHBO1401- Mitsuba). J Hepatobiliary Pancreat Sci 2023; 30: 102\u201310.","DOI":"10.1002\/jhbp.1219"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18) Merters J, Lamarca A. Integrating cytotoxic, targeted and immune therapies for cholangiocarcinoma. J Hepatol 2023; 78: 652\u20137.","DOI":"10.1016\/j.jhep.2022.11.005"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19) Chen X, Wang D, Liu J, et al. Genomic alterations in biliary tract cancer predict prognosis and immunotherapy outcomes. J Immunother Cancer 2021; 9: e003214.","DOI":"10.1136\/jitc-2021-003214"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20) Jian Z, Fan J, Shi GM, et al. Gemox chemotherapy in combination with anti-PD1 antibody toripalimab and lenvatinib as first-line treatment for advanced intrahepatic cholangiocarcinoma: a phase 2 clinical trial. J Clin Oncol 2021; 39 (15_suppl): 4094.","DOI":"10.1200\/JCO.2021.39.15_suppl.4094"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21) Schvartsman G, Peng SA, Bis G, et al. Response rates to single-agent chemotherapy after exposure to immune checkpoint inhibitors in advanced non-small cell lung cancer. Lung Cancer 2017; 112: 90\u20135.","DOI":"10.1016\/j.lungcan.2017.07.034"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22) Saleh K, Daste A, Martin N, et al. Response to salvage chemotherapy after progression on immune checkpoint inhibitors in patients with recurrent and\/or metastatic squamous cell carcinoma of the head and neck. Eur J Cancer 2019; 121: 123\u20139.","DOI":"10.1016\/j.ejca.2019.08.026"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23) Yabushita Y, Park JS, Yoon YS, et al. Conversion surgery for initially unresectable locally advanced biliary tract cancer: a multicenter collaborative study conducted in Japan and Korea. J Hepatobiliary Pancreat Sci 2024; 31: 481\u201391.","DOI":"10.1002\/jhbp.1437"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24) Noji T, Nagayama M, Imai K, et al. Conversion surgery for initially unresectable biliary malignancies: a multicenter retrospective cohort study. Surg Today 2020; 50: 1409\u201317.","DOI":"10.1007\/s00595-020-02031-5"}],"container-title":["Surgical Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/scrj\/11\/1\/11_cr.25-0023\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,23]],"date-time":"2025-03-23T05:36:00Z","timestamp":1742708160000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/scrj\/11\/1\/11_cr.25-0023\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.70352\/scrj.cr.25-0023","relation":{},"ISSN":["2198-7793"],"issn-type":[{"value":"2198-7793","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025]]},"article-number":"cr.25-0023"}}